EUVIMEDEUVIMED entdecken
Multizentrische Studie

Long‐Term Outcomes of Chenodeoxycholic Acid Therapy for Cerebrotendinous Xanthomatosis: A Nationwide Study on Prognostic Factors and Treatment Response

Tanyel Zubarioglu iD, Banu Kadıoğlu-Yılmaz, Engin Köse, Pelin Teke-Kısa, Mehmet Cihan Balcı iD, Havva Yazıcı, Burcu Özturk-Hişmi, Abdurrahman Akgün, Deniz Kor, Sevil Yıldız iD, Gonca Kılıç-Yıldırım, Erdoğan Soyuçen und 20 weitere

Journal of Inherited Metabolic Disease · 2025

DOI: 10.1002/jimd.70069 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von Tanyel Zubarioglu und 31 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Nutrition and Metabolism, İstanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, İstanbul, Turkey. Hauptthemen laut MEDLINE: Chenodeoxycholic Acid, Xanthomatosis, Cerebrotendinous. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cerebrotendinous xanthomatosis (CTX) is a treatable neurometabolic disorder. Chenodeoxycholic acid (CDCA) is the first‐line treatment and can potentially halt disease progression if initiated before neurologic symptoms appear. This nationwide, multicenter study evaluates the long‐term effects of treatment in 86 genetically confirmed patients with CTX receiving CDCA for ≥ 6 months, focusing on neurologic and extraneurologic outcomes, prognostic factors, and biochemical response. Clinical and biochemical parameters were recorded at baseline and follow‐up, and neurological outcomes were assessed using neurological disability scores. Our results indicate a critical age of 28 years for the start of treatment. Patients diagnosed before 28 years showed 100% neurological stabilization or improvement, whereas patients diagnosed later had a higher rate of disease progression ( p < 0.05). CDCA effectively stabilized or improved pyramidal and cerebellar symptoms, although myoclonus and parkinsonism remained less responsive. Psychiatric symptoms showed a lower treatment response, with psychosis being the most refractory finding. CDCA resulted in a strong and sustained reduction in cholestanol levels, although biochemical response did not always correlate with clinical improvement. Longer diagnostic delay and presence of anxiety and pyramidal/cerebellar symptoms were associated with poorer outcomes. Notably, a cholestatic child, for whom liver transplantation had initially been considered, recovered completely under CDCA therapy. Our results show that early diagnosis and initiation of CDCA therapy significantly improve neurological outcomes in CTX. However, even in late‐diagnosed patients, treatment continues to be beneficial, demonstrating that it is never too late to start therapy. Biochemical response does not always predict clinical improvement; multidisciplinary follow‐up is essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chenodeoxycholic AcidXanthomatosis, CerebrotendinousHumansMaleFemaleAdultPrognosisTreatment OutcomeYoung AdultAdolescentChildMiddle AgedDisease ProgressionChild, PreschoolCholestanol

Stichwörter der Autor:innen

CYP27A1cerebrotendinouschenodeoxycholic acidprognosisxanthomatosis

Substanzen

Chenodeoxycholic AcidCholestanol

Autor:innen und Institutionen

  • Division of Pediatric Nutrition and Metabolism, İstanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, İstanbul, Turkey.
  • Division of Pediatric Nutrition and Metabolism, Konya Selçuk University Medical Faculty, Konya, Turkey.
  • Department of Pediatric Metabolism, Ankara University Faculty of Medicine, Ankara, Turkey.
  • Ankara University Rare Diseases Application and Research Center, Ankara, Turkey.
  • Division of Pediatric Nutrition and Metabolism, Dokuz Eylul University Medical Faculty, İzmir, Turkey.
  • Division of Nutrition and Metabolism, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey.

ORCID-Profile: Tanyel Zubarioglu, Mehmet Cihan Balcı, Sevil Yıldız, Yılmaz Yıldız, Halil Tuna Akar, Nur Arslan, Ayşegül Gündüz, Ertuğrul Kıykım

Zitieren

APA

Zubarioglu, T., Kadıoğlu-Yılmaz, B., Köse, E., Teke-Kısa, P., Balcı, M. C., Yazıcı, H., Özturk-Hişmi, B., Akgün, A., Kor, D., Yıldız, S., Kılıç-Yıldırım, G., Soyuçen, E., Akçalı, A., Yıldız, Y., Durmuş, A., Güneş, D., Soylu-Üstkoyuncu, P., Kasapkara, Ç. S., Erdöl, Ş., …, & Aktuğlu-Zeybek, Ç. (2025). Long‐Term Outcomes of Chenodeoxycholic Acid Therapy for Cerebrotendinous Xanthomatosis: A Nationwide Study on Prognostic Factors and Treatment Response. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70069

Vancouver

Zubarioglu T, Kadıoğlu-Yılmaz B, Köse E, Teke-Kısa P, Balcı MC, Yazıcı H, et al. Long‐Term Outcomes of Chenodeoxycholic Acid Therapy for Cerebrotendinous Xanthomatosis: A Nationwide Study on Prognostic Factors and Treatment Response. Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.70069

BibTeX
@article{Zubarioglu2025,
  author = {Zubarioglu, Tanyel and Kadıoğlu-Yılmaz, Banu and Köse, Engin and Teke-Kısa, Pelin and Balcı, Mehmet Cihan and Yazıcı, Havva and Özturk-Hişmi, Burcu and Akgün, Abdurrahman and Kor, Deniz and Yıldız, Sevil and Kılıç-Yıldırım, Gonca and Soyuçen, Erdoğan and Akçalı, Aylin and Yıldız, Yılmaz and Durmuş, Aslı and Güneş, Dilek and Soylu-Üstkoyuncu, Pembe and Kasapkara, Çiğdem Seher and Erdöl, Şahin and Göksoy, Emine and Akar, Halil Tuna and Gümüş, Haluk and Ekmekçi, Ahmet Hakan and Eminoğlu, Fatma Tuba and Arslan, Nur and Hanağası, Haşmet Ayhan and Canda, Ebru and Genç, Emine and Özer, Işıl and Gündüz, Ayşegül and Kıykım, Ertuğrul and Aktuğlu-Zeybek, Çiğdem},
  title = {Long‐Term Outcomes of Chenodeoxycholic Acid Therapy for Cerebrotendinous Xanthomatosis: A Nationwide Study on Prognostic Factors and Treatment Response},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  doi = {10.1002/jimd.70069}
}
Kostenlos starten →